{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:03Z","timestamp":1791976503765,"version":"4.4.0"},"reference-count":57,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2021-0165_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Recently, there is an increased number of reports being published on Methotrexate (MTX) related cutaneous manifestations. We aimed to identify and critically appraise descriptive studies describing the MTX related skin manifestations, treatment approach, and their outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2021-0165_abs_002\">\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>An extensive literature search was performed in the PubMed, Embase, and Scopus databases from inception to April 2021 without any restrictions along with the bibliographic search of included studies, grey literature search, and a snowball search was performed in Google and Google Scholar to identify the relevant literature. Descriptive studies reporting MTX related cutaneous manifestations were considered for the review. The study selection, data extraction, and quality assessment were conducted by two independent reviewers and any disagreements were settled by consensus with the third reviewer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2021-0165_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 out of 8,365 descriptive studies including 38 patients (22 females and 16 males) aged between 12 and 78\u00a0years prescribed for the management of rheumatoid arthritis, ankylosing spondylitis, and psoriasis were included in this review. Toxic epidermal necrolysis (TEN), papular eruption, vasculitis, erosions of psoriasis, ulcerated psoriatic plaques, local reactions, keratinocyte dystrophy, erythema multiforme, drug rash with eosinophilia and systemic symptoms, Steven Johnson syndrome and photosensitive dermatitis were the majority of MTX induced cutaneous reactions. Immediate withdrawal of MTX, providing appropriate care with anti-inflammatory, topical steroids, and supplementation with folic acid were reported to be effective for the management of the MTX related cutaneous manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2021-0165_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians and healthcare professionals should be aware of possible acute cutaneous drug reactions induced by MTX to avoid further consequences and fatal conditions. Immediate withdrawal of MTX and supportive care were reported as an efficacious therapeutic management of acute cutaneous drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2021-0165_abs_005\">\n                    <jats:title>PROSPERO Registration number<\/jats:title>\n                    <jats:p>CRD42020220038.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2021-0165","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T18:43:51Z","timestamp":1635360231000},"page":"549-565","source":"Crossref","is-referenced-by-count":16,"title":["Methotrexate related cutaneous adverse drug reactions: a systematic literature review"],"prefix":"10.1515","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-7551","authenticated-orcid":false,"given":"Mohammed","family":"Zuber","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-9871","authenticated-orcid":false,"family":"Harikrishna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-1989","authenticated-orcid":false,"family":"Vidhyashree","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8924-8242","authenticated-orcid":false,"given":"Manik","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , ISF College of Pharmacy , Moga , Punjab , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-9617","authenticated-orcid":false,"given":"Rajesh","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-0969","authenticated-orcid":false,"given":"Sathish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-7764","authenticated-orcid":false,"given":"Muhammed","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , Nagamangala , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_001","doi-asserted-by":"crossref","unstructured":"Czarnecka-Operacz, M, Sadowska-Przytocka, A. The possibilities and principles of methotrexate treatment of psoriasis\u2013the updated knowledge. Postepy Dermatol Alergol 2014;31:392, https:\/\/doi.org\/10.5114\/pdia.2014.47121.","DOI":"10.5114\/pdia.2014.47121"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_002","doi-asserted-by":"crossref","unstructured":"Sheagren, JN. Staphylococcus aureus: the persistent pathogen. N Engl J Med 1984;310:1437\u201342, https:\/\/doi.org\/10.1056\/nejm198405313102206.","DOI":"10.1056\/NEJM198405313102206"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_003","unstructured":"Weinblatt, ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 2013;124:16."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_004","doi-asserted-by":"crossref","unstructured":"Singh, JA, Saag, KG, Bridges, SLJr, Akl, EA, Bannuru, RR, Sullivan, MC, et al.. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1\u201326., https:\/\/doi.org\/10.1002\/art.39480.","DOI":"10.1002\/art.39480"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_005","doi-asserted-by":"crossref","unstructured":"Elmets, CA, Korman, NJ, Prater, EF, Wong, EB, Rupani, RN, Kivelevitch, D, et al.. Joint AAD\u2013NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432\u201370, https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_006","doi-asserted-by":"crossref","unstructured":"Bedoui, Y, Guillot, X, S\u00e9lambarom, J, Guiraud, P, Giry, C, Jaffar-Bandjee, MC, et al.. Methotrexate an old drug with new tricks. Int J Mol Sci 2019;20:5023, https:\/\/doi.org\/10.3390\/ijms20205023.","DOI":"10.3390\/ijms20205023"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_007","unstructured":"Smith, BJ, Cohen, S, Kremer, JM, Winthrop, K, Fahey, S, Genovese, M. American College of Rheumatology updated guideline for the management of rheumatoid arthritis Project Plan 2018:1\u201335. Available at: https:\/\/www.rheumatology.org\/Portals\/0\/Files\/Rheumatoid-Arthritis-Guideline-Project-Plan.pdf."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_008","doi-asserted-by":"crossref","unstructured":"Visser, K, van der Heijde, D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094\u20139, https:\/\/doi.org\/10.1136\/ard.2008.092668.","DOI":"10.1136\/ard.2008.092668"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_009","doi-asserted-by":"crossref","unstructured":"Montaudi\u00e9, H, Sbidian, E, Paul, C, Maza, A, Gallini, A, Aractingi, S, et al.. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25:12\u20138, https:\/\/doi.org\/10.1111\/j.1468-3083.2011.03991.x.","DOI":"10.1111\/j.1468-3083.2011.03991.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_010","unstructured":"Henderson, ES, Adamson, RH, Oliverio, VT. The metabolic fate of tritiated methotrexate: II. Absorption and excretion in man. Cancer Res 1965;25:1018\u201324."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_011","doi-asserted-by":"crossref","unstructured":"Grim, J, Chl\u00e1dek, J, Mart\u00ednkov\u00e1, J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003;42:139\u201351, https:\/\/doi.org\/10.2165\/00003088-200342020-00003.","DOI":"10.2165\/00003088-200342020-00003"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_012","doi-asserted-by":"crossref","unstructured":"Robey, RB, Block, CA. Adverse effects of low-dose methotrexate. Ann Intern Med 2020;173:166\u20137, https:\/\/doi.org\/10.7326\/l20-0524.","DOI":"10.7326\/L20-0524"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_013","doi-asserted-by":"crossref","unstructured":"Watkins, PB, Seeff, LB. Drug\u2010induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618\u201331, https:\/\/doi.org\/10.1002\/hep.21095.","DOI":"10.1002\/hep.21095"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_014","doi-asserted-by":"crossref","unstructured":"Taylor, P, Balsa Criado, A, Mongey, AB, Avouac, J, Marotte, H, Mueller, RB. How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?-MTX in the treat-to-target strategy. J Clin Med 2019;8:515, https:\/\/doi.org\/10.3390\/jcm8040515.","DOI":"10.3390\/jcm8040515"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_015","doi-asserted-by":"crossref","unstructured":"Jeurissen, ME, Boerbooms, AT, Van de Putte, LB. Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Clin rheumatol. 1989;8:417\u20139, https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04256.x.","DOI":"10.1007\/BF02030360"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_016","doi-asserted-by":"crossref","unstructured":"Singal, A, Sonthalia, S, Pandhi, D. Erythema gyratum repens-like eruption occuring in resolving psoriasis during methotrexate therapy. Int J Dermatol. 2010;49:306. https:\/\/doi.org\/10.1515\/jbcpp-2020-0115.","DOI":"10.1111\/j.1365-4632.2009.04256.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_017","doi-asserted-by":"crossref","unstructured":"Rashid, M, Kashyap, A, Undela, K. Valproic acid and Stevens\u2010Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol 2019;58:1014\u201322, https:\/\/doi.org\/10.1111\/ijd.14411.","DOI":"10.1111\/ijd.14411"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_018","doi-asserted-by":"crossref","unstructured":"Rashid, M, Rajan, AK, Chhabra, M, Kashyap, A. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure 2020;75:101\u20139, https:\/\/doi.org\/10.1016\/j.seizure.2020.01.002.","DOI":"10.1016\/j.seizure.2020.01.002"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_019","unstructured":"Howick, J, Chalmers, I, Glasziou, P. The oxford 2011 levels of evidence. Oxford, UK: Oxford Centre for Evidence-Based Medicine; 2011. Available at: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_020","doi-asserted-by":"crossref","unstructured":"Murad, MH, Sultan, S, Haffar, S, Bazerbachi, F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018;23:60\u20133, https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_021","doi-asserted-by":"crossref","unstructured":"Goerttler, E, Kutzner, H, Peter, HH, Requena, L. Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. J Am Acad Dermatol 1999;40:702\u20137, https:\/\/doi.org\/10.1016\/s0190-9622(99)70150-7.","DOI":"10.1016\/S0190-9622(99)70150-7"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_022","doi-asserted-by":"crossref","unstructured":"Lewis, HA, Nemer, KM, Chibnall, RJ, Musiek, AC. Methotrexate-induced cutaneous ulceration in 3 nonpsoriatic patients: report of a rare side effect. JAAD Case Rep 2017;3:236\u20139, https:\/\/doi.org\/10.1016\/j.jdcr.2017.02.002.","DOI":"10.1016\/j.jdcr.2017.02.002"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_023","doi-asserted-by":"crossref","unstructured":"Pearce, HP, Wilson, BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol 1996;35:835\u20138, https:\/\/doi.org\/10.1016\/s0190-9622(96)90097-3.","DOI":"10.1016\/S0190-9622(96)90097-3"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_024","doi-asserted-by":"crossref","unstructured":"Wong, SM, Chong, YT, Thevarajah, S, Baba, R. Methotrexate toxicity presenting as ulcerated psoriatic plaques. Australas J Dermatol 2012;53:81\u20133, https:\/\/doi.org\/10.1111\/j.1440-0960.2011.00779.x.","DOI":"10.1111\/j.1440-0960.2011.00779.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_025","doi-asserted-by":"crossref","unstructured":"Primka, EJIII, Camisa, C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 1997;36:815\u20138, https:\/\/doi.org\/10.1016\/s0190-9622(97)70029-x.","DOI":"10.1016\/S0190-9622(97)70029-X"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_026","doi-asserted-by":"crossref","unstructured":"Salg\u00fcero, I, Moreno, C, Aguayo-Leiva, I, Harto, A. Papuloerythroderma of Ofuji associated with chronic lymphatic leukaemia. Eur J Dermatol 2009;19:396\u20137, https:\/\/doi.org\/10.1684\/ejd.2009.0689.","DOI":"10.1684\/ejd.2009.0689"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_027","doi-asserted-by":"crossref","unstructured":"Priego-Recio, CM, Camacho-Martinez, FM. Local reaction after subcutaneous injection of methotrexate: uncommon side effect. J Eur Acad Dermatol Venereol. 2014;30:523\u20134, https:\/\/doi.org\/10.1111\/jdv.12918.","DOI":"10.1111\/jdv.12920"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_028","doi-asserted-by":"crossref","unstructured":"Borman, P, Bodur, H, G\u00fcle\u00e7, AT, Ucan, H, Se\u00e7kin, \u00dc, Mocan, G. Atypical methotrexate dermatitis and vasculitis in a patient with ankylosing spondylitis. Rheumatol Int 2000;19:191\u20133,https:\/\/doi.org\/10.1007\/s002960000047.","DOI":"10.1007\/s002960000047"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_029","doi-asserted-by":"crossref","unstructured":"Simonart, TH, Durez, P, Margaux, J, Van Geertruyden, J, Goldschmidt, D, Parent, D. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity. Clin Rheumatol 1997;16:623\u20135, https:\/\/doi.org\/10.1007\/bf02247805.","DOI":"10.1007\/BF02247805"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_030","doi-asserted-by":"crossref","unstructured":"Mebazaa, A, Kenani, N, Denguezli, M, SCB, Ziadi, S, Sriha, B, et al.. Methotrexate-induced papular eruption following treatment of psoriasis. Ann Pharmacother 2008;42:138\u201341, https:\/\/doi.org\/10.1345\/aph.1k271.","DOI":"10.1345\/aph.1K271"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_031","doi-asserted-by":"crossref","unstructured":"Behera, B, Kumari, R, Gochhait, D, Thappa, DM. Low dose methotrexate induced asymptomatic keratinocyte dystrophy in a patient of psoriasis vulgaris. J Cutan Pathol 2016;43:1238\u201341, https:\/\/doi.org\/10.1111\/cup.12810.","DOI":"10.1111\/cup.12810"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_032","unstructured":"Omoregie, FO, Ukpebor, M, Saheeb, BD. Methotrexate-induced erythema multiforme: a case report and review of the literature. West Afr J Med 2011;30:377\u20139."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_033","doi-asserted-by":"crossref","unstructured":"Teraki, Y, Izaki, S. Salazosulfapyridine-induced hypersensitivity syndrome triggered by methotrexate. Clin Exp Dermatol 2009;34:e287\u20138, https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03212.x.","DOI":"10.1111\/j.1365-2230.2009.03212.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_034","doi-asserted-by":"crossref","unstructured":"Thami, GP, Kaur, S, Kanwar, AJ. Delayed reactivation of haloperidol induced photosensitive dermatitis by methotrexate. Postgrad Med 2002;78:116\u20137, https:\/\/doi.org\/10.1136\/pmj.78.916.116.","DOI":"10.1136\/pmj.78.916.116"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_035","doi-asserted-by":"crossref","unstructured":"Gupta, A, Sardana, K, Bhardwaj, M, Singh, A. Methotrexate cutaneous toxicity following a single dose of 10\u00a0mg in a case of chronic plaque psoriasis: a possible idiosyncratic reaction. Indian Dermatol Online J 2018;9:328, https:\/\/doi.org\/10.4103\/idoj.IDOJ_316_17.","DOI":"10.4103\/idoj.IDOJ_316_17"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_036","doi-asserted-by":"crossref","unstructured":"Kurian, A, Haber, R. Methotrexate-induced cutaneous ulcers in a nonpsoriatic patient: case report and review of the literature. J Cutan Med Surg 2011;15:275\u20139, https:\/\/doi.org\/10.2310\/7750.2011.10078.","DOI":"10.2310\/7750.2011.10078"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_037","doi-asserted-by":"crossref","unstructured":"Al-Saffar, F, Ibrahim, S, Patel, P, Jacob, R, Palacio, C, Cury, J. Skin rash in the intensive care unit: Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rare manifestation of a hidden cutaneous malignancy: a case report. Mol Clin Oncol 2016;4:413\u20135, https:\/\/doi.org\/10.3892\/mco.2015.713.","DOI":"10.3892\/mco.2015.713"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_038","doi-asserted-by":"crossref","unstructured":"Tekur, VK. Methotrexate-induced nonhealing cutaneous ulcers in a nonpsoriatic patient without pancytopenia. Indian Dermatol Online J 2016;7:418, https:\/\/doi.org\/10.4103\/2229-5178.190509.","DOI":"10.4103\/2229-5178.190509"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_039","doi-asserted-by":"crossref","unstructured":"Torner, O, Ruber, C, Olive, A, Tena, X. Methotrexate related cutaneous vasculitis. Clin Rheumatol 1997;16:108, https:\/\/doi.org\/10.1007\/bf02238776.","DOI":"10.1007\/BF02238776"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_040","doi-asserted-by":"crossref","unstructured":"Kazlow, DW, Federgrun, D, Kurtin, S, Lebwohl, MG. Cutaneous ulceration caused by methotrexate. J Am Acad Dermatol 2003;49:197\u20138, https:\/\/doi.org\/10.1067\/mjd.2003.388.","DOI":"10.1067\/mjd.2003.388"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_041","doi-asserted-by":"crossref","unstructured":"Hsu, MC, Chen, CC. Low-dose methotrexate-induced ulcerated psoriatic plaques: a rare case. JAAD Case Rep 2015;1:264\u20136, https:\/\/doi.org\/10.1016\/j.jdcr.2015.06.003.","DOI":"10.1016\/j.jdcr.2015.06.003"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_042","doi-asserted-by":"crossref","unstructured":"Riquelme-Mc Loughlin, C, Giavedoni, P, Mascar\u00f3, JMJr. More than skin deep. Am J Emerg Med 2018;36:1719\u2013e3, https:\/\/doi.org\/10.1016\/j.ajem.2018.05.069.","DOI":"10.1016\/j.ajem.2018.05.069"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_043","doi-asserted-by":"crossref","unstructured":"Skrek, SV, Timoshchuk, EA, Sidikov, AA, Zaslavsky, DV, Megna, M. Kaposi varicelliform eruption induced by methotrexate in an adult atopic dermatitis patient. Dermatol Ther 2019;32:e12826, https:\/\/doi.org\/10.1111\/dth.12826.","DOI":"10.1111\/dth.12826"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_044","doi-asserted-by":"crossref","unstructured":"Borcea, A, Greaves, MW. Methotrexate\u2010induced exacerbation of urticarial vasculitis: an unusual adverse reaction. Br J Dermatol 2000;143:203\u20134, https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03624.x.","DOI":"10.1046\/j.1365-2133.2000.03624.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_045","doi-asserted-by":"crossref","unstructured":"Arora, S, Abidi, A, Fatima, F, Hasan, R, Rizvi, D, Thadani, A. Methotrexate induced Stevens Johnson syndrome: a rare case report. Era\u2019s J Med Res 2018;5:194\u20136, https:\/\/doi.org\/10.24041\/ejmr2018.95.","DOI":"10.24041\/ejmr2018.95"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_046","doi-asserted-by":"crossref","unstructured":"Reed, KM, Sober, AJ. Methotrexate-induced necrolysis. J Am Acad Dermatol 1983;8:677\u20139, https:\/\/doi.org\/10.1016\/s0190-9622(83)70079-4.","DOI":"10.1016\/S0190-9622(83)70079-4"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_047","doi-asserted-by":"crossref","unstructured":"Alaya, Z, Mokni, S, Guerfala, M, Salem, CB, Sriha, B, Nouira, R, et al.. Acute severe cutaneous methotrexate toxicity in a patient with rheumatoid arthritis: report of a rare side effect. Egypt Rheumatol 2018;40:281\u20134,https:\/\/doi.org\/10.1016\/j.ejr.2017.08.004.","DOI":"10.1016\/j.ejr.2017.08.004"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_048","doi-asserted-by":"crossref","unstructured":"Sako, EY, Famenini, S, Wu, JJ. Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate. J Am Acad Dermatol 2013;69:e264\u20135, https:\/\/doi.org\/10.1016\/j.jaad.2013.07.012.","DOI":"10.1016\/j.jaad.2013.07.012"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_049","doi-asserted-by":"crossref","unstructured":"Blanes, M, Silvestre, JF, Albares, MP, Pascual, JC, Pastor, N. Erythema multiforme due to methotrexate reproduced with patch test. Contact Dermatitis 2005;52:164\u20135, https:\/\/doi.org\/10.1111\/j.0105-1873.2005.0548f.x.","DOI":"10.1111\/j.0105-1873.2005.0548f.x"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_050","doi-asserted-by":"crossref","unstructured":"Rajan, AK, Kashyap, A, Chhabra, M, Rashid, M. Linezolid induced skin reactions in a multi drug resistant infective endocarditis patient: a rare case. Curr Drug Saf 2020;15:222\u20136, https:\/\/doi.org\/10.2174\/1574886315666200516175053.","DOI":"10.2174\/1574886315666200516175053"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_051","doi-asserted-by":"crossref","unstructured":"Kearsley-Fleet, L, Vicente Gonz\u00e1lez, L, Steinke, D, Davies, R, De Cock, D, Baildam, E, et al.. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology 2019;58:1453\u20138, https:\/\/doi.org\/10.1093\/rheumatology\/kez048.","DOI":"10.1093\/rheumatology\/kez048"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_052","doi-asserted-by":"crossref","unstructured":"Lalani, R, Lyu, H, Vanni, K, Solomon, DH. Low\u2010dose methotrexate and mucocutaneous adverse events: results of a systematic literature review and meta\u2010analysis of randomized controlled trials. Arthritis Care Res 2020;72:1140\u20136, https:\/\/doi.org\/10.1002\/acr.23999.","DOI":"10.1002\/acr.23999"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_053","doi-asserted-by":"crossref","unstructured":"Frikha, R, Jemaa, MB, Frikha, F, Turki, I, Elloumi, M, Keskes, L, et al.. Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia. J Oncol Pharm Pract 2021;27:1382\u20137, https:\/\/doi.org\/10.1177\/1078155220951898.","DOI":"10.1177\/1078155220951898"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_054","unstructured":"McKendry, RJ, Dale, P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850\u20136."},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_055","doi-asserted-by":"crossref","unstructured":"Del Campo, M, Kosaki, K, Bennett, FC, Jones, KL. Developmental delay in fetal aminopterin\/methotrexate syndrome. Teratology 1999;60:10\u20132, https:\/\/doi.org\/10.1002\/(sici)1096-9926(199907)60:1<10::aid-tera5>3.0.co;2-h.","DOI":"10.1002\/(SICI)1096-9926(199907)60:1<10::AID-TERA5>3.0.CO;2-H"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_056","doi-asserted-by":"crossref","unstructured":"Liu, L, Liu, S, Wang, C, Guan, W, Zhang, Y, Hu, W, et al.. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol 2019;25:197\u2013202, https:\/\/doi.org\/10.1097\/rhu.0000000000000810.","DOI":"10.1097\/RHU.0000000000000810"},{"key":"2025121209103717725_j_jbcpp-2021-0165_ref_057","doi-asserted-by":"crossref","unstructured":"Destiani, DP, Naja, S, Dewi, S, Rahmadi, AR, Sulaiman, SA, Abdulah, R. Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials. Osteoporos Int 2020:1\u20132, https:\/\/doi.org\/10.1007\/s00198-020-05743-z.","DOI":"10.1007\/s00198-020-05743-z"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2021-0165\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2021-0165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:44:40Z","timestamp":1765539880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2021-0165\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,29]]},"published-print":{"date-parts":[[2022,9,26]]}},"alternative-id":["10.1515\/jbcpp-2021-0165"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2021-0165","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}